Creabilis has a strong understanding of the science underlying a wide range of dermatological conditions drawn from its academic history and the expertise of its in-house team. In particular, the Company focuses on inflammation/immunology, kinase inhibition and cytokine networking. This knowledge is the foundation on which the Company has built a broad-based approach to drug discovery and development that encompasses a number of technologies to address high potential targets.
Sede della società: via Ribes 5, 10010 Colleretto Giacosa (TO), Italy - Ufficio del Registro delle Imprese di Torino numero 08661490014 - Capitale sociale versato 1.500.000,00 Euro - Socio Unico: Creabilis SA